K2M Group Holdings, Inc. has had 6 insider trades in the last 3 months, including 0 open market buys and 6 sells. Barclays Capital maintained K2M Group Holdings Inc (NASDAQ:KTWO) rating on Thursday, August 4.
K2M Group Holdings (NASDAQ:KTWO) just had their share rating of a "Buy" issued by research analysts at UBS, who now has a $24 target price on the $799.52 million market cap company or a 29.94 % upside potential. Looking at a shorter time period, shares have been seen -28.53% away from the 50 day high and -9.40% off the 50 day low price.Covering sell-side analysts have recently weighed in on shares of K2M Group Holdings, Inc. Oppenheimer Holdings, Inc. reaffirmed a buy rating on shares of K2M Group Holdings in a research report on Thursday, June 22nd.
The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $781.52M. K2M Group Holdings has an average rating of Buy and an average price target of $25.60. The stock of K2M Group Holdings Inc (NASDAQ:KTWO) has "Market Outperform" rating given on Friday, April 8 by JMP Securities. 413,776 shares of the company were exchanged. The stock's 50 day moving average price is $21.94 and its 200 day moving average price is $22.52. K2M Group Holdings has a 1-year low of $16.32 and a 1-year high of $25.99.
10/09/2017 - K2M Group Holdings, Inc. had its "outperform" rating reiterated by analysts at Cowen. The medical device company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The company now has a Return on Equity (ROE) of -15.4 and a Return on Investment (ROI) of -10.4. (CYTX) has a market cap of $15.1 million and over the last 12 months, Cytori Therapeutics, Inc. They expect $-0.16 earnings per share, up 15.79% or $0.03 from last year's $-0.19 per share. K2M Group Holdings's revenue for the quarter was up 11.0% on a year-over-year basis.
COPYRIGHT VIOLATION WARNING: "K2M Group Holdings, Inc". This volatility measure use for multipurpose in judging the underlying price momentum as well as the rate of change in KTWO's price. If you are viewing this piece on another site, it was illegally copied and republished in violation of USA & worldwide copyright law. Ubs Group Ag now controls 12,600 shares with a value of $307,000. The shares were sold at an average price of $23.37, for a total transaction of $919,773.09.
In other K2M Group Holdings news, insider John Philip Md Kostuik sold 1,332 shares of the business's stock in a transaction that occurred on Wednesday, August 23rd. The disclosure for this sale can be found here. The stock decreased 1.74% or $0.78 during the last trading session, reaching $44.09. However, the institutional investors are observed to own 0.00% of the total shares. As of quarter end Ghost Tree Capital, LLC had sold 135,000 shares trimming its stake by 47.4%. Legal & General Group Plc now owns 6,763 shares of the medical device company's stock worth $138,000 after acquiring an additional 564 shares during the period. Wellington Management Group LLP increased its holdings in K2M Group Holdings by 10.4% in the first quarter. Schroder Investment Management Group increased its holdings in K2M Group Holdings by 1.6% in the second quarter. The Procter & Gamble Company (NYSE:PG) consensus analyst target price is $93.74. William Blair also issued estimates for K2M Group Holdings' Q3 2017 earnings at ($0.18) EPS, Q4 2017 earnings at ($0.15) EPS, FY2017 earnings at ($0.80) EPS, Q1 2018 earnings at ($0.20) EPS, Q2 2018 earnings at ($0.14) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at $0.01 EPS and FY2018 earnings at ($0.43) EPS. Vanguard Group Inc. now owns 1,550,592 shares of the medical device company's stock valued at $37,772,000 after buying an additional 171,502 shares in the last quarter.